Table 1

Patient characteristics

IL-12 treated (n = 10)Control (n = 20)
Men416
Women64
Age55.4 (46.1-69.1)57.8 (36.7-69.2)
WHO performance1 (0-1)1 (0-1)
Primary tumor site
    Oral cavity814
    Oropharynx26
Tumor stage
    T133
    T2510
    T316
    T411
Lymph node stage
    N046
    N135
    N2a12
    N2b27
Surgery of the neck
    MRND714
    SOHD36
  • NOTE. No significant differences between the IL-12-treated and control patients were noted.

    Abbreviations: MRND, modified radical neck lymph node dissection; SOHD, supraomohyoid lymph node dissection.